This is a Moderna news story, published by CNBC, that relates primarily to Covid news.
For more Moderna news, you can click here:
more Moderna newsFor more Covid news, you can click here:
more Covid newsFor more vaccine development news, you can click here:
more vaccine development newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about vaccine development, you might also like this article about
newer vaccine method. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest vaccine news, vaccines news, news about vaccine development, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Covid vaccineCNBC
•
83% Informative
The Food and Drug Administration authorized Novavax 's updated protein-based Covid vaccine for emergency use in people ages 12 and up on Friday .
The FDA 's decision comes only a week after it approved a new round of messenger RNA shots from Pfizer and Moderna , which both target an offshoot of JN.1 called KP.1.
VR Score
85
Informative language
88
Neutral language
7
Article tone
formal
Language
English
Language complexity
56
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
3
Source diversity
3
Affiliate links
no affiliate links